These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10218517)

  • 1. Re: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
    Cameron DA; Leonard RC
    J Natl Cancer Inst; 1999 Apr; 91(8):728-9. PubMed ID: 10218517
    [No Abstract]   [Full Text] [Related]  

  • 2. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
    Thor AD; Berry DA; Budman DR; Muss HB; Kute T; Henderson IC; Barcos M; Cirrincione C; Edgerton S; Allred C; Norton L; Liu ET
    J Natl Cancer Inst; 1998 Sep; 90(18):1346-60. PubMed ID: 9747866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
    Paik S; Bryant J; Park C; Fisher B; Tan-Chiu E; Hyams D; Fisher ER; Lippman ME; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 1998 Sep; 90(18):1361-70. PubMed ID: 9747867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Mehta RS; Schubbert T
    J Natl Cancer Inst; 2008 May; 100(9):680; author reply 680-1. PubMed ID: 18445822
    [No Abstract]   [Full Text] [Related]  

  • 6. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
    Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
    Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
    Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
    J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients.
    Wiltschke C; Kindas-Muegge I; Steininger A; Reiner A; Reiner G; Preis PN
    J Cancer Res Clin Oncol; 1994; 120(12):737-42. PubMed ID: 7798300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
    Muss HB; Thor AD; Berry DA; Kute T; Liu ET; Koerner F; Cirrincione CT; Budman DR; Wood WC; Barcos M
    N Engl J Med; 1994 May; 330(18):1260-6. PubMed ID: 7908410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.
    Ellis GK; Livingston RB; Gralow JR; Green SJ; Thompson T
    J Clin Oncol; 2002 Sep; 20(17):3637-43. PubMed ID: 12202664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream.
    Di Leo A; Moretti E
    J Clin Oncol; 2008 Nov; 26(31):5011-3. PubMed ID: 18768431
    [No Abstract]   [Full Text] [Related]  

  • 16. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.
    Paik S; Bryant J; Tan-Chiu E; Yothers G; Park C; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2000 Dec; 92(24):1991-8. PubMed ID: 11121461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No gains in efficacy observed by adding gemcitabine to adjuvant therapy for lymph node-positive breast cancer.
    Barton MK
    CA Cancer J Clin; 2014; 64(1):1-2. PubMed ID: 24436115
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer.
    Wang W; Tang M; Zhang L; Xu X; Qi X; Yang Y; Jin F; Chen B
    Jpn J Clin Oncol; 2013 Dec; 43(12):1170-6. PubMed ID: 24106298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.